A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
Myelodysplastic Syndromes
DRUG: Darbepoetin Alfa
The proportion of subjects achieving an erythroid response during the 13-week test period
The proportion of subjects achieving an erythroid response during the 28-week treatment period|The change in Hb from baseline|The incidence of red blood cell (RBC) transfusions (greater than or equal to 1 unit)|The change in FACT-F from baseline
The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).